Ascendis Pharma announced that the company has entered into an exclusive license agreement with Teijin Limited for the further development and commercialization of TransCon hGH, TransCon PTH, and TransCon CNP for endocrinology rare disease in Japan. Under the terms of the agreement, Ascendis will receive an upfront payment of $70M, with additional development and regulatory milestones of up to $175M, transfer pricing and commercial milestones. In addition, Ascendis Pharma is eligible to receive royalties on net sales in Japan, of up to mid-20’s percent, varying by product.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ASND:
- Ascendis Pharma Announces Strategic Partnership with Teijin Limited in Japan
- Ascendis Pharma price target raised to $124 from $115 at BofA
- Ascendis Pharma announces EC approval of YORVIPATH
- Citi opens ‘upside Catalyst Watch’ on Ascendis into FDA feedback
- Ascendis Pharma resubmits NDA for TransCon PTH to U.S. FDA